Auris Health is making some big moves in the healthcare industry. The company has secured a massive $220m in funding, a huge step towards expanding its reach.
This significant investment will help Auris Health further develop its innovative robotic-assisted surgical systems. These systems have the potential to revolutionize the way surgeons operate.
The funding boost also comes with a strategic acquisition by Johnson & Johnson, a leading healthcare company. This partnership will undoubtedly give Auris Health a significant boost in terms of resources and expertise.
Recommended read: Draftkings Boost
J&J Acquires Inc
Johnson & Johnson acquired Auris Health, Inc. for approximately $3.4 billion in cash.
The acquisition was completed on April 1, 2019, marking a significant milestone in Johnson & Johnson's digital surgery portfolio.
Auris Health's robotic platform technology is currently used in diagnostic and therapeutic procedures in the lung.
With this technology, Johnson & Johnson aims to advance its commitment to combatting lung cancer.
Additional contingent payments of up to $2.35 billion may be payable upon reaching certain predetermined milestones.
For your interest: Auris Health Lux Capital
The passionate team and differentiated innovation from Auris will help Johnson & Johnson amplify the power of digital surgery to address unmet clinical needs.
Johnson & Johnson's acquisition of Auris Health complements its existing robotic platform technologies in general surgery and orthopaedics.
The company aspires to bring disruptive innovation to the full continuum of procedures, including open, laparoscopic, robotic, and endoluminal.
Recommended read: Does Insurance Cover Arm Lift Surgery
Acquisition Completion
Johnson & Johnson has completed the acquisition of Auris Health, Inc. for approximately $3.4 billion in cash.
The acquisition was announced on April 1, 2019, marking a significant milestone for Johnson & Johnson in its pursuit of digital surgery and better patient outcomes.
Auris Health's robotic platform technology will enable Johnson & Johnson to advance its commitment to combatting lung cancer and expand its digital surgery portfolio across multiple surgical specialties.
The technology complements Johnson & Johnson's existing robotic platform technologies in general surgery and orthopaedics.
Johnson & Johnson aims to bring disruptive innovation to the full continuum of procedures, including open, laparoscopic, robotic, and endoluminal.
Additional contingent payments of up to $2.35 billion may be payable upon reaching certain predetermined milestones.
The passionate team and differentiated innovation from Auris will help Johnson & Johnson amplify the power of digital surgery to address unmet clinical needs and lead a transformation in surgical care and lung cancer intervention.
Johnson & Johnson is committed to using its reach and size for good, striving to improve access and affordability, create healthier communities, and put a healthy mind, body, and environment within reach of everyone, everywhere.
Explore further: Reach Plc
Frequently Asked Questions
What does Auris Health do?
Auris Health develops innovative medical platforms that enhance physician capabilities and improve patient outcomes through minimally invasive techniques and new categories of care. Based in Silicon Valley, the company is pioneering a new era of medical intervention.
Who is the CEO of Auris Health?
Frederic H. Moll, MD is the Chairman and CEO of Auris Health. He leads the company from its headquarters in Redwood City, CA.
Featured Images: pexels.com
